ARTICLE | Clinical News
J&J highlights FGFR inhibitor data ahead of ASCO
May 18, 2018 7:10 PM UTC
Johnson & Johnson (NYSE:JNJ) unveiled for the first time data for its fibroblast growth factor receptor (FGFR) inhibitor, erdafitinib (JNJ-42756493). In the Phase II BLC2001 trial, erdafitinib led to a confirmed objective response rate (ORR) of 70% in 21 evaluable urothelial carcinoma patients who received prior immune checkpoint inhibitors.
The data were released in an abstract ahead of the American Society of Clinical Oncology (ASCO) meeting in Chicago...
BCIQ Target Profiles